Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133944 | 0.92 | CRBN (0.56) | CRBNEGFRBRD9DDB1ERBB2 | |
| SCHEMBL25691397 | 0.88 | CRBN (0.45) | CRBNEGFRBRD9DDB1ERBB2 | |
| SCHEMBL25691395 | 0.85 | CRBN (0.48) | CRBNBRD9DDB1 | |
| SCHEMBL25691407 | 0.82 | CRBN (0.55) | CRBNDDB1HPGDS | |
| SCHEMBL25691118 | 0.81 | CRBN (0.54) | CRBNEGFRBRD9DDB1ERBB2 | |
| SCHEMBL25691423 | 0.80 | CRBN (0.47) | CRBNEGFRDDB1ERBB2ERBB3 | |
| SCHEMBL25691418 | 0.80 | CRBN (0.47) | CRBNEGFRDDB1HPGDS | |
| SCHEMBL27099498 | 0.78 | CRBN (0.59) | CRBNEGFRBRD9DDB1HPGDS | |
| SCHEMBL23133942 | 0.77 | CRBN (0.61) | CRBNBRD9DDB1 | |
| SCHEMBL23172313 | 0.77 | CRBN (0.63) | CRBNEGFRDDB1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885EGFR 56/4885BRD9 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.